250 related articles for article (PubMed ID: 34277839)
1. Turning 'Cold' tumors 'Hot': immunotherapies in sarcoma.
Rytlewski J; Milhem MM; Monga V
Ann Transl Med; 2021 Jun; 9(12):1039. PubMed ID: 34277839
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in Sarcoma: Where Do Things Stand?
Moreno Tellez C; Leyfman Y; D'Angelo SP; Wilky BA; Dufresne A
Surg Oncol Clin N Am; 2022 Jul; 31(3):381-397. PubMed ID: 35715140
[TBL] [Abstract][Full Text] [Related]
3. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
4. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
Zhu MMT; Shenasa E; Nielsen TO
Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
[TBL] [Abstract][Full Text] [Related]
5. Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas.
Kerrison WGJ; Lee ATJ; Thway K; Jones RL; Huang PH
Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327375
[TBL] [Abstract][Full Text] [Related]
6. New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas.
Seong G; D'Angelo SP
Front Oncol; 2023; 13():1150765. PubMed ID: 37007160
[TBL] [Abstract][Full Text] [Related]
7. Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Kösemehmetoğlu K; Özoğul E; Babaoğlu B; Tezel GG; Gedikoğlu G
Turk Patoloji Derg; 2017; 1(1):192-197. PubMed ID: 28832074
[TBL] [Abstract][Full Text] [Related]
8. Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies.
Gujar S; Pol JG; Kroemer G
Oncoimmunology; 2018; 7(8):e1442169. PubMed ID: 30221036
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for sarcomas.
Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
[TBL] [Abstract][Full Text] [Related]
10. Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities.
Jeong S; Afroz S; Kang D; Noh J; Suh J; Kim JH; You HJ; Kang HG; Kim YJ; Kim JH
Mol Cells; 2023 Oct; 46(10):579-588. PubMed ID: 37853684
[TBL] [Abstract][Full Text] [Related]
11. PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Torabi A; Amaya CN; Wians FH; Bryan BA
Pathology; 2017 Aug; 49(5):506-513. PubMed ID: 28688724
[TBL] [Abstract][Full Text] [Related]
12. Sarcomas-A barren immunological wasteland or field of opportunity for immunotherapy?
Atherton MJ; Lenz JA; Mason NJ
Vet Comp Oncol; 2020 Dec; 18(4):447-470. PubMed ID: 32246517
[TBL] [Abstract][Full Text] [Related]
13. Turning cold tumors hot: from molecular mechanisms to clinical applications.
Zhang J; Huang D; Saw PE; Song E
Trends Immunol; 2022 Jul; 43(7):523-545. PubMed ID: 35624021
[TBL] [Abstract][Full Text] [Related]
14. Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis.
You Y; Guo X; Zhuang R; Zhang C; Wang Z; Shen F; Wang Y; Liu W; Zhang Y; Lu W; Hou Y; Wang J; Zhang X; Lu M; Zhou Y
Front Mol Biosci; 2021; 8():747650. PubMed ID: 34869583
[No Abstract] [Full Text] [Related]
15. Current molecular and therapeutic advances in liposarcoma, rhabdomyosarcoma, leiomyosarcoma, synovial sarcoma, and angiosarcoma.
Tanriverdi O; Yildiz A
J Oncol Pharm Pract; 2022 Apr; 28(3):635-645. PubMed ID: 35043739
[TBL] [Abstract][Full Text] [Related]
16. Exploring the landscape of immunotherapy approaches in sarcomas.
Pilavaki P; Panagi M; Arifi S; Jones RL; Stylianopoulos T; Constantinidou A
Front Oncol; 2022; 12():1069963. PubMed ID: 36686827
[TBL] [Abstract][Full Text] [Related]
17. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.
Paydas S; Bagir EK; Deveci MA; Gonlusen G
Med Oncol; 2016 Aug; 33(8):93. PubMed ID: 27421997
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas.
Zhang Y; Chen Y; Papakonstantinou A; Tsagkozis P; Linder-Stragliotto C; Haglund F
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204793
[TBL] [Abstract][Full Text] [Related]
19. Current Landscape of Immunotherapy for Advanced Sarcoma.
Albarrán V; Villamayor ML; Pozas J; Chamorro J; Rosero DI; San Román M; Guerrero P; Pérez de Aguado P; Calvo JC; García de Quevedo C; González C; Vaz MÁ
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190214
[TBL] [Abstract][Full Text] [Related]
20. Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials.
Tang F; Tie Y; Wei YQ; Tu CQ; Wei XW
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188606. PubMed ID: 34371128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
